JP Morgan Chase
PACB icon

JP Morgan Chase’s Pacific Biosciences PACB Stock Holding History

JP Morgan Chase’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Sell
138,504
-318,404
-70% -$570K ﹤0.01% 5541
2025
Q4 		$854K Sell
456,908
-11,972
-3% -$23K ﹤0.01% 4709
2025
Q3 		$600K Sell
468,880
-11,622
-2% -$15.7K ﹤0.01% 4915
2025
Q2 		$596K Sell
480,502
-40,832
-8% -$47.2K ﹤0.01% 4684
2025
Q1 		$615K Buy
521,334
+6,829
+1% +$10.5K ﹤0.01% 4648
2024
Q4 		$942K Sell
514,505
-50,002
-9% -$97.6K ﹤0.01% 4676
2024
Q3 		$960K Buy
564,507
+45,957
+9% +$75.5K ﹤0.01% 4492
2024
Q2 		$710K Sell
518,550
-342,843
-40% -$692K ﹤0.01% 4486
2024
Q1 		$3.23M Sell
861,393
-421,879
-33% -$2.47M ﹤0.01% 3457
2023
Q4 		$12.6M Sell
1,283,272
-219,163
-15% -$1.79M ﹤0.01% 2241
2023
Q3 		$12.5M Buy
1,502,435
+173,562
+13% +$1.98M ﹤0.01% 2057
2023
Q2 		$17.7M Buy
1,328,873
+119,997
+10% +$1.46M ﹤0.01% 1795
2023
Q1 		$14M Buy
1,208,876
+392,455
+48% +$3.9M ﹤0.01% 1962
2022
Q4 		$6.68M Buy
816,421
+98,497
+14% +$849K ﹤0.01% 2595
2022
Q3 		$4.17M Sell
717,924
-60,500
-8% -$347K ﹤0.01% 2895
2022
Q2 		$3.44M Sell
778,424
-237,395
-23% -$1.44M ﹤0.01% 3102
2022
Q1 		$9.24M Buy
1,015,819
+748,630
+280% +$8.62M ﹤0.01% 2448
2021
Q4 		$5.47M Buy
267,189
+19,052
+8% +$460K ﹤0.01% 2977
2021
Q3 		$6.34M Sell
248,137
-50,877
-17% -$1.51M ﹤0.01% 2831
2021
Q2 		$10.5M Sell
299,014
-289,477
-49% -$8.42M ﹤0.01% 2390
2021
Q1 		$19.6M Buy
588,491
+364,640
+163% +$12.8M ﹤0.01% 1778
2020
Q4 		$5.81M Buy
223,851
+161,652
+260% +$2.75M ﹤0.01% 2680
2020
Q3 		$610K Buy
62,199
+13,259
+27% +$76.3K ﹤0.01% 3893
2020
Q2 		$169K Sell
48,940
-1,039,206
-96% -$3.54M ﹤0.01% 4337
2020
Q1 		$3.33M Buy
1,088,146
+786,673
+261% +$3.22M ﹤0.01% 2580
2019
Q4 		$1.55M Sell
301,473
-17,911
-6% -$91K ﹤0.01% 3566
2019
Q3 		$1.65M Buy
319,384
+6,568
+2% +$36.7K ﹤0.01% 3540
2019
Q2 		$1.88M Sell
312,816
-562,894
-64% -$3.95M ﹤0.01% 3428
2019
Q1 		$6.33M Buy
875,710
+603,401
+222% +$4.36M ﹤0.01% 2402
2018
Q4 		$2.02M Buy
272,309
+235,508
+640% +$1.49M ﹤0.01% 3265
2018
Q3 		$199K Buy
36,801
+12,061
+49% +$51.8K ﹤0.01% 4691
2018
Q2 		$88K Sell
24,740
-5,361
-18% -$14.9K ﹤0.01% 4884
2018
Q1 		$62K Buy
30,101
+7,744
+35% +$20.1K ﹤0.01% 4745
2017
Q4 		$59K Buy
+22,357
New +$78.3K ﹤0.01% 4842
2017
Q3 		– Sell
-34,370
Closed -$122K – 5115
2017
Q2 		$122K Sell
34,370
-66,040
-66% -$266K ﹤0.01% 4112
2017
Q1 		$519K Sell
100,410
-31,051
-24% -$152K ﹤0.01% 3693
2016
Q4 		$500K Buy
131,461
+27,382
+26% +$199K ﹤0.01% 3769
2016
Q3 		$933K Buy
104,079
+49,169
+90% +$411K ﹤0.01% 3165
2016
Q2 		$386K Buy
54,910
+25,346
+86% +$232K ﹤0.01% 3539
2016
Q1 		$251K Sell
29,564
-11,103
-27% -$109K ﹤0.01% 3548
2015
Q4 		$535K Buy
40,667
+29,880
+277% +$268K ﹤0.01% 3366
2015
Q3 		$39K Buy
+10,787
New +$52.7K ﹤0.01% 3804
2015
Q2 		– Sell
-140,355
Closed -$819K – 4132
2015
Q1 		$819K Buy
140,355
+100,855
+255% +$695K ﹤0.01% 3307
2014
Q4 		$310K Buy
+39,500
New +$253K ﹤0.01% 3854
2014
Q1 		– Sell
-15,891
Closed -$84K – 3846
2013
Q4 		$84K Sell
15,891
-23,217
-59% -$107K ﹤0.01% 3927
2013
Q3 		$216K Buy
39,108
+28,255
+260% +$98.1K ﹤0.01% 4015
2013
Q2 		$28K Buy
+10,853
New +$27K ﹤0.01% 4315

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase's PACB Position: Q1 2026 in Review

JP Morgan Chase reduced its Pacific Biosciences (PACB) stake by 70% in Q1 2026, selling an estimated $570K and leaving 138,504 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

JP Morgan Chase first reported a position in PACB in Q2 2013 and has held it in 47 quarters since. The position peaked at $19.6M in Q1 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • JP Morgan Chase held 138,504 shares of Pacific Biosciences worth $175K as of Q1 2026.
  • JP Morgan Chase sold 318,404 Pacific Biosciences shares in Q1 2026, an estimated $570K.
  • Pacific Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5541 holding.
  • JP Morgan Chase first reported a position in Pacific Biosciences in Q2 2013 and has held it in 47 quarters since.
  • JP Morgan Chase's Pacific Biosciences position peaked at $19.6M in Q1 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.